Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT CORVUS PHARMACEUTICALS INC.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)
Listen to this Section


$11.30
-0.4200 ( -3.58% ) 580.5K

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Clinical Trial Pipeline Stages


Drug Name Stage
Soquelitinib (CPI-818) (ITK inhibitor)DetailsCancer, Blood cancer, Peripheral T-cell Lymphomas Phase 3
Mupadolimab (CPI-006) (Anti-CD73)DetailsLung cancer, Renal cell carcinoma, Cancer, Non-small cell lung carcinoma Phase 2
Soquelitinib (CPI-818) (ITK inhibitor)DetailsRenal cell carcinoma, Cancer Phase 2
Ciforadenant (A2AR inhibitor) +/- ipilimumab and nivolumabDetailsRenal cell carcinoma, Cancer Phase 1/2
Mupadolimab + pembrolizumabDetailsHead and neck cancer, Cancer, Non-small cell lung carcinoma Phase 1b
Soquelitinib (CPI-818) (ITK inhibitor)DetailsAtopic dermatitis, Skin disease/disorder Phase 1
Mupadolimab (CPI-0060 (B-cell activation) (CD73 inhibitor)DetailsCOVID-19 Failed

Market Data


Open $11.30
Previous Close $11.72
Volume 580.5K
Market Cap $975.45M
Day Range $11.27 - $11.93
52 Week Range $3.55 - $26.95
Shares Outstanding 84.09M
Change % -3.58%
Net Change ▼ -0.4200
Insider Ownership -0.14%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2016
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 1,718,788.00

Date Type Amount Purchased Purchaser
2024-06-17 Sale -15000.00 Morrison Scott W
2024-06-17 Sale -15000.00 Gould Terry P
2024-06-17 Sale -15000.00 Grais Linda
2024-06-17 Sale -15000.00 CLARK IAN T
2024-06-17 Sale -15000.00 Thompson Peter A.
2024-05-14 Sale -302016.00 MILLER RICHARD A MD
2024-05-08 Buy 1444085.00 Thompson Peter A.
2024-05-08 Buy 1444085.00 ORBIMED ADVISORS LLC
2024-05-07 Buy 577634.00 MILLER RICHARD A MD
2024-05-07 Buy 20000.00 Jones William Benton

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 16, 2025
4 Insider transactions 1 Jun 16, 2025
4 Insider transactions 1 Jun 16, 2025
8-k 8K-related 12 Jun 13, 2025
4 Insider transactions 1 Jun 06, 2025
8-k 8K-related 20 Jun 04, 2025

Latest News


× Before browsing our site, please accept our cookies policy